News of Note—Emergent’s new CEO, Valneva’s chikungunya vaccine and more

newspapers
(Pixabay)

Here is some other vaccine news of note for the week:

> Emergent BioSolutions announced that its CEO since 2012, Daniel J. Abdun-Nabi, will retire and be replaced by Robert G. Kramer, Sr., the company’s current president and COO, effective Apr. 1, 2019. Release

> Valneva reported positive phase 1 interim results for its chikungunya vaccine candidate, VLA1553, showing a single vaccination achieved a 100% seroconversion rate at Day 28. The news came as the company announced plans to delist from the Vienna Stock Exchange to focus trading on Euronext Paris. Release | Release

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

> Walter Ricciardi, president of Italy’s National Institute of Health, has resigned, accusing the League and Five Star Movement-led government’s antivaccine stance and other “unfounded” health claims. The BMJ article

> The Coalition for Epidemic Preparedness Innovations is making $48 million of funding available to support development of vaccines against Rift Valley fever and chikungunya. Release

Suggested Articles

An FDA panel gave Sanofi's Dengvaxia a mixed endorsement, voting down its use in people 17 and older.

Prosecutors in the Philippines have found probable cause to indict six Sanofi officials for its Dengvaxia rollout.

The FDA has issued guidance on continuous manufacturing and is allocating $58 million to move forward advanced manufacturing processes.